LabCorp Pulls OvaSure, But Charges FDA With Overreaching
This article was originally published in The Gray Sheet
Executive Summary
Laboratory Corporation of America pulled its early-stage ovarian cancer test service from the market last week in response to FDA scrutiny, but the lab giant called the agency's actions leading up to the withdrawal "unprecedented.